A011502 (ABC) Aspirin in Preventing Recurrence of Cancer in Patients with Node Positive or High Risk Node Negative, HER2 Negative Breast Cancer after Chemotherapy, Surgery, and / or Radiation Therapy - Mercy Medical Center

A011502 (ABC) Aspirin in Preventing Recurrence of Cancer in Patients with Node Positive or High Risk Node Negative, HER2 Negative Breast Cancer after Chemotherapy, Surgery, and / or Radiation Therapy

Posted on: January 30, 2020

This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with node positive or high risk node negative, human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy, surgery, and / or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer. Eligibility includes being at least 18 years old and:

•Histologic documentation of women or men with HER2 negative breast carcinoma and free of recurrence;

patients must be registered within 18 months of diagnosis;

•Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined by the treating physician, is allowed; the last dose of chemotherapy or radiation therapy must be at least 30 days prior to study registration; concurrent hormonal therapy is allowed

•Regular nonsteroidal anti-inflammatory drug (NSAID)/aspirin use at any dose (including baby aspirin) (defined as >= 5 days per week) is allowed if aspirin and/or NSAIDs are stopped for 30 days prior to study entry and throughout the study period; participants will be encouraged to use acetaminophen for minor pain and fever

Leave a Reply

Mercy Medical Center | 1320 Mercy Drive NW, Canton, OH 44708 | info@cantonmercy.org
Contact Us | Careers | Privacy Policy | Copyright © 2017 Mercy Medical Center